Maximus, Inc. (NYSE:MMS – Get Rating) declared a quarterly dividend on Tuesday, July 12th, Zacks reports. Shareholders of record on Monday, August 15th will be given a dividend of 0.28 per share by the health services provider on Wednesday, August 31st. This represents a $1.12 dividend on an annualized basis and a yield of 1.82%. The ex-dividend date is Friday, August 12th.
Maximus has raised its dividend by an average of 42.8% annually over the last three years. Maximus has a dividend payout ratio of 27.7% indicating that its dividend is sufficiently covered by earnings. Research analysts expect Maximus to earn $5.25 per share next year, which means the company should continue to be able to cover its $1.12 annual dividend with an expected future payout ratio of 21.3%.
Maximus stock opened at $61.48 on Wednesday. Maximus has a 12-month low of $56.50 and a 12-month high of $89.78. The company has a quick ratio of 1.45, a current ratio of 1.45 and a debt-to-equity ratio of 0.89. The business’s 50-day moving average price is $63.39 and its two-hundred day moving average price is $71.81. The stock has a market cap of $3.78 billion, a PE ratio of 15.41 and a beta of 0.69.
Maximus (NYSE:MMS – Get Rating) last released its earnings results on Wednesday, May 4th. The health services provider reported $1.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.98 by $0.09. The firm had revenue of $1.18 billion for the quarter, compared to analysts’ expectations of $1.07 billion. Maximus had a return on equity of 20.46% and a net margin of 5.34%. The business’s revenue for the quarter was up 22.7% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.29 earnings per share. As a group, analysts expect that Maximus will post 4.18 earnings per share for the current year.
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.
And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!
In other news, Director Raymond B. Ruddy purchased 17,341 shares of the company’s stock in a transaction on Tuesday, June 14th. The stock was purchased at an average price of $57.72 per share, with a total value of $1,000,922.52. Following the completion of the purchase, the director now directly owns 109,030 shares in the company, valued at approximately $6,293,211.60. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Bruce Caswell purchased 8,300 shares of the company’s stock in a transaction on Wednesday, June 15th. The shares were purchased at an average cost of $60.32 per share, with a total value of $500,656.00. Following the purchase, the chief executive officer now owns 181,017 shares of the company’s stock, valued at $10,918,945.44. The disclosure for this purchase can be found here. 1.10% of the stock is owned by company insiders.
Several institutional investors and hedge funds have recently added to or reduced their stakes in MMS. Covestor Ltd increased its holdings in shares of Maximus by 92.8% in the first quarter. Covestor Ltd now owns 1,604 shares of the health services provider’s stock worth $120,000 after buying an additional 772 shares during the period. PNC Financial Services Group Inc. increased its holdings in Maximus by 16.3% during the 1st quarter. PNC Financial Services Group Inc. now owns 2,520 shares of the health services provider’s stock valued at $188,000 after purchasing an additional 354 shares during the period. Point72 Hong Kong Ltd purchased a new position in Maximus during the 1st quarter valued at about $235,000. Cetera Investment Advisers increased its holdings in Maximus by 4.5% during the 1st quarter. Cetera Investment Advisers now owns 4,253 shares of the health services provider’s stock valued at $319,000 after purchasing an additional 184 shares during the period. Finally, Sawtooth Solutions LLC bought a new stake in Maximus during the 1st quarter valued at approximately $334,000. Hedge funds and other institutional investors own 93.23% of the company’s stock.
MMS has been the subject of a number of analyst reports. StockNews.com initiated coverage on shares of Maximus in a research note on Thursday, March 31st. They set a “hold” rating for the company. TheStreet downgraded shares of Maximus from a “b-” rating to a “c+” rating in a research note on Tuesday, May 31st.
About Maximus (Get Rating)
Maximus, Inc provides business process services (BPS) to government health and human services programs. It operates through three segments: U.S. Services, U.S. Federal Services, and Outside the U.S. The U.S. Services segment offers various BPS solutions, such as program administration, appeals and assessments, and related consulting works for U.S.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Should you invest $1,000 in Maximus right now?
Before you consider Maximus, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Maximus wasn’t on the list.
While Maximus currently has a “N/A” rating among analysts, top-rated analysts believe these five stocks are better buys.
Source: marketbeat.com
